Euleria Health, an innovative startup and Benefit Corporation from Trentino, known for developing devices and platforms for rehabilitative treatments in orthopedic, neurological, and sports contexts, has completed a capital increase round to facilitate its scale-up.

Euleria Health: from early stage to scale-up

Founded in 2020 through the efforts of David Tacconi and Roberto Tomasi, and with support from the Bio4Dreams incubator, Euleria Health has achieved significant growth over four years. It has expanded its operations to 12 countries worldwide and become a benchmark in the rehabilitative technology sector, involving over 1,000 professionals and assisting more than 30,000 patients. These achievements have marked the transition from the early-stage phase to scale-up, prompting the company to strengthen its solution portfolio and expand its presence in international markets, particularly in recently activated ones like the United States and China.

Growth phase and new management

This growth phase will be consolidated by the new CEO, Dr. Paolo Girardi, who has significant experience in management and strategic development, gained through senior roles at GPI Group, HIT – Hub Innovazione Trentino, and most recently at Anffas Trentino Onlus.

With the shift to scale-up, Euleria Health concludes its incubation period at Bio4Dreams, although it remains within the incubator’s portfolio as a participating entity.

The investment, equally subscribed by Bio4Dreams, Brixia, and a|impact, reaffirms the commitment to support Euleria Health in this new chapter of its history, continuing alongside other partners and the new management with the goal of supporting the company’s expansion and consolidation in the global rehabilitative technology markets.

📈 See the dedicated investor page.